Welcome to Cardiology Today – Recorded November 22, 2025. This episode summarizes 5 key cardiology studies on topics like omics sciences and retrospective cohort study. Key takeaway: Carotid Stenosis: Revascularize or Meds?. Article Links: Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis. (The New England journal of medicine) Article 2: Coronary revascularization: a long-term perspective. (European heart journal) Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. (ESC heart failure) Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial. (JACC. Cardiovascular interventions) Article 5: Cardiac Risk Factors in Drug-Resistant Tuberculosis Patients on Bedaquiline: A Retrospective Cohort Study. (Cardiology) Full episode page: https://podcast.explainheart.com/podcast/carotid-stenosis-revascularize-or-meds-11-22-25/ Featured Articles Article 1: Medical Management and Revascularization for Asymptomatic Carotid Stenosis. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41269206 Summary: The clinical approach for asymptomatic carotid stenosis remains uncertain, particularly whether revascularization offers benefits beyond intensive medical management alone. Two parallel, observer-blinded clinical trials were conducted to address this critical question. These trials enrolled patients with high-grade (70 percent or greater) asymptomatic carotid stenosis across 155 centers in five countries. The research directly compared stenting or endarterectomy against intensive medical management to determine optimal patient care strategies. Article 2: Coronary revascularization: a long-term perspective. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41271218 Summary: This paper provided a long-term perspective on advancements in coronary revascularization, building on successful predictions made in 2000 regarding innovations like drug-eluting stents and coronary computed tomography angiography. The authors highlighted the evolving landscape of coronary artery disease treatment. They specifically emphasized the transformative role of artificial intelligence and omics sciences. Imagenomics, which integrates imaging and omics, was identified as a key future tool for precision in coronary revascularization by 2040. Article 3: Indirect mitral annuloplasty in patients with reduced or preserved ejection fraction: A real-world, single-centre experience. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41255167 Summary: This single-center retrospective study evaluated the real-world effectiveness and safety of the Carillon Mitral Contour System (C. M. C. S.) for indirect annuloplasty in 204 consecutive patients. The study cohort presented with Heart Failure (H. F.) and moderate or moderate to severe (grade two plus or three plus) secondary mitral regurgitation (S. M. R.), with an average age of 83 years, 68 percent female, and 72 percent having Heart Failure with Reduced Ejection Fraction (H. F. rEF). Echocardiographic variables, B-type natriuretic peptide (B. N. P.) levels, and clinical outcomes were systematically recorded. These comprehensive data were collected at baseline, 6-month, and 1-year follow-up to characterize the treatment’s impact on this specific patient group. Article 4: Rationales Behind Physiology-Guided Revascularization: Diagnostic Impact of Quantitative Flow Ratio in the FAVOR III China Trial. Journal: JACC. Cardiovascular interventions PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41263729 Summary: Physiology-guided percutaneous coronary intervention (P. C. I.) is known to offer clinical benefits by optimizing treatment plans beyond what coronary angiography alone can achieve. This study investigated the diagnostic impact of quantita

Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like mortality and blood pressure. Key takeaway: CAR T Cells Halt Atherosclerosis. Article Links: Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. (Circulation) Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age. (JAMA cardiology) Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. (Heart (British Cardiac Society)) Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. (Heart (British Cardiac Society)) Article 5: Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. (Heart (British Cardiac Society)) Full episode page: https://podcast.explainheart.com/podcast/car-t-cells-halt-atherosclerosis-11-21-25/ Featured Articles Article 1: OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41268661 Summary: This study found that oxidized low-density lipoprotein targeted chimeric antigen receptor T regulatory cells reduced atherosclerotic plaque development. This novel approach represents a significant therapeutic advance for cardiovascular disease, which is driven by oxidized low-density lipoprotein accumulation and foam cell formation. The findings suggest a new medical therapy for patients ineligible for percutaneous interventions, addressing a major unmet need in atherosclerosis treatment. Article 2: Blood Pressure in Adolescence and Atherosclerosis in Middle Age. Journal: JAMA cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259058 Summary: This study found a significant association between elevated systolic and diastolic blood pressure during adolescence and the development of atherosclerosis in middle age. The findings demonstrated that elevated adolescent blood pressure is linked to long-term subclinical atherosclerotic cardiovascular disease. This highlights the critical importance of early blood pressure management to mitigate future cardiovascular risk. Article 3: Patient characteristics, valve surgery and 1-year mortality in left-sided Staphylococcus aureus infective endocarditis: a nationwide study. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41266240 Summary: A nationwide study characterized patient profiles and one-year mortality rates for left-sided Staphylococcus aureus infective endocarditis, a condition known for 30 percent to 40 percent in-hospital mortality. The research demonstrated the comparative outcomes between patients who underwent valve surgery and those who received medical therapy alone. These findings offer robust evidence essential for refining current guidelines on surgical intervention in Staphylococcus aureus infective endocarditis. Article 4: Diagnostic performance of 2023 endocarditis criteria in patients with and without cardiac implantable electronic devices. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41218924 Summary: This multicenter cohort study evaluated the diagnostic performance of the 2023 European Society of Cardiology criteria for infective endocarditis. The findings demonstrated how these new criteria performed compared to the 2015 European Society of Cardiology, 2019 European Heart Rhythm Association, and 2023 Duke-International Society for Cardiovascular Infectious Diseases classifications. This assessment of diagnostic accuracy was conducted in patients with and without cardiac implantable electronic devices, providing critical insights for clinical application. Article 5: Percutaneous ventricular assist devices

Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes.. Article Links: Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma. (The New England journal of medicine) Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies. (European heart journal) Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. (European heart journal) Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. (European heart journal) Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. (European heart journal) Full episode page: https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/ Featured Articles Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41124218 Summary: Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease. Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40824531 Summary: High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer’s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials. Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40669514 Summary: Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease. Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40599126 Summary: surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these cr

Welcome to Cardiology Today – Recorded November 20, 2025. This episode summarizes 5 key cardiology studies on topics like angiography and heart failure hospitalization. Key takeaway: Aspirin Elimination Cuts LVAD Bleeding Risk. Article Links: Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. (European heart journal) Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. (European heart journal) Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. (JACC. Heart failure) Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. (JACC. Heart failure) Article 5: Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes. (JACC. Heart failure) Full episode page: https://podcast.explainheart.com/podcast/aspirin-elimination-cuts-lvad-bleeding-risk-11-20-25/ Featured Articles Article 1: Cardiac endogenous transmitter system: molecular features, functions, and clinical implications. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259103 Summary: Recent studies have identified several endogenous transmitter systems within cardiomyocytes and cardiac pacemaker cells, overturning the traditional belief that the heart lacked its own intrinsic signaling networks. These systems represent molecular networks that facilitate signal transmission directly within cardiac tissues. This discovery reveals that the heart possesses its own distinct intrinsic networks for transmitting signals. The findings provide novel insights into cardiac physiology and potential targets for therapeutic interventions. Article 2: Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41259082 Summary: The OCCUPI trial investigated the impact of optical coherence tomography guidance compared to angiography guidance in patients with complex coronary lesions. This study classified patients who underwent optical coherence tomography-guided percutaneous coronary intervention into two groups based on meeting specific optimization criteria. This classification system enabled the detailed evaluation of the incidence, determinants, and clinical impact of stent optimization. The trial established a structured approach for assessing optimal stent placement using advanced imaging techniques. Article 3: Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial. Journal: JACC. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258851 Summary: Patients with hypoplastic left heart syndrome frequently experience severe right ventricle dysfunction, often leading to shortened lifespans. Neonatal cardiac progenitor cells previously demonstrated improved right ventricle performance in animal models of pressure-overload induced dysfunction. The C. H. I. L. D. trial, a phase one randomized study, specifically applied this therapeutic strategy to patients with hypoplastic left heart syndrome. This trial represents a key step in evaluating autologous neonatal cardiac progenitor cells for enhancing right ventricle function in this vulnerable pediatric group. Article 4: Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial. Journal: JACC. Heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41258850 Summary: The Antiplatelet Removal and Hemocompatibility Events With the HeartMate three Pump trial demonstrated both safety and decreased bleeding by eliminating aspirin from the antithrombotic regimen for patients implanted with a HeartMate three left ventricular as

Welcome to Cardiology Today – Recorded November 19, 2025. This episode summarizes 5 key cardiology studies on topics like heart failure and stroke. Key takeaway: ECG Abnormalities Predict Heart Failure Risk. Article Links: Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes. (Heart (British Cardiac Society)) Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices. (Heart (British Cardiac Society)) Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts. (Heart (British Cardiac Society)) Article 4: Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study. (ESC heart failure) Article 5: Impact of Left Atrial v-Wave Following Mitral Edge-to-Edge Repair on Survival: The MITRA-PRO Registry. (Journal of the American Heart Association) Full episode page: https://podcast.explainheart.com/podcast/ecg-abnormalities-predict-heart-failure-risk-11-19-25/ Featured Articles Article 1: Isolated non-specific electrocardiographic ST-T abnormalities and risk of incident heart failure and its subtypes. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41249037 Summary: Isolated non-specific S. T. T. abnormalities on electrocardiograms were found to be associated with an increased risk of incident coronary heart disease and stroke in participants free of these conditions at baseline. This study also found that these abnormalities were linked to an increased risk of incident heart failure and its subtypes. Data showed that these specific electrocardiographic patterns, defined by Minnesota E. C. G. classification, independently predicted future development of heart failure, including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. These findings establish a prognostic role for isolated non-specific S. T. T. abnormalities in identifying individuals at risk for future cardiovascular events and heart failure. Article 2: Estimating 5-year absolute risk of cardiovascular disease using routinely collected electronic medical records from Australian general practices. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41249035 Summary: This study demonstrated the feasibility and performance of using routinely collected electronic medical records from Australian general practices to estimate the 5-year absolute risk of cardiovascular disease. Researchers found that integrating primary care electronic medical record data, specifically from the New South Wales Health Lumos program, provided a viable approach for cardiovascular risk prediction. The study successfully utilized data from 680 general practices to assess the predictive capability of these records. These findings indicate that Australian healthcare systems can effectively leverage existing electronic medical records for robust cardiovascular disease risk estimation, comparable to methods used in the U. S. A. and U. K. Article 3: Comparing diagnostic tools for heart failure with preserved ejection fraction across community and clinical cohorts. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41249034 Summary: This study demonstrated the comparative diagnostic accuracy of several tools for heart failure with preserved ejection fraction (H. F. pEF) across community and clinical cohorts. Researchers found that the Heart Failure Association-P. E. F. F. and H. two F. P. E. F. Scores showed differing diagnostic performance when compared against inclusion criteria from sodium-glucose cotransporter-two inhibitors trials and age-adjusted N-terminal pro B-type natriuretic peptide. The data provided clarification on the strengths and limitations of each diagnostic ap

Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like precision medicine and temporal trends. Key takeaway: Cirrhotic Cardiomyopathy Predicts Post-Transplant Heart Failure. Article Links: Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes. (Circulation) Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study. (European heart journal) Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome. (European heart journal) Article 4: Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation. (Transplantation) Article 5: Role of physician assistants and their impact on cardiology specialty training in the United Kingdom. (Heart (British Cardiac Society)) Full episode page: https://podcast.explainheart.com/podcast/cirrhotic-cardiomyopathy-predicts-post-transplant-heart-failure-11-18-25/ Featured Articles Article 1: CD4+ Tregs Regulate Heart Growth and Regeneration Through MRG15/TIP60-Mediated Epigenomic Remodeling in Proliferating Cardiomyocytes. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41251000 Summary: The study demonstrated that CD4 positive T regulatory cells regulate heart growth and regeneration. This regulation occurs through M. R. G. fifteen / T. I. P. sixty mediated epigenomic remodeling within proliferating cardiomyocytes. The chromatin regulatory network was found to be crucial in orchestrating the dynamic changes in gene expression for the regenerative response in the neonatal heart. These findings provide a deeper understanding of the mechanisms controlling heart regeneration, which is critical for addressing limited regenerative capacity in the adult mammalian heart. Article 2: Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41251006 Summary: This nationwide Danish study analyzed temporal trends in the use of oral anticoagulants and associated clinical outcomes in older patients with new-onset atrial fibrillation. The study found that anticoagulation therapy patterns in patients with atrial fibrillation have evolved significantly over time, especially following the introduction of direct oral anticoagulants. The analysis investigated how these changes in anticoagulant uptake have impacted clinical outcomes across older adults (65-74 years), elderly (75-84 years), and very elderly (85 years and older) patient groups. This provides critical information on how treatment strategies and patient prognoses for atrial fibrillation have shifted in an aging population. Article 3: Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41251004 Summary: The study demonstrated that automated patch clamp data significantly improves the classification of S. C. N. five A variants and penetrance stratification for Brugada Syndrome. This approach addresses complications in genetic workup arising from S. C. N. five A variants of uncertain significance and incomplete penetrance. The deployment of an S. C. N. five A Brugada Syndrome functional assay at a cohort scale was found to facilitate the implementation of genetic and precision medicine for this inherited arrhythmia disorder. These findings refine the diagnostic and risk stratification process for the approximately 20 percent of Brugada Syndrome patients with rare S. C. N. five A variants. Article 4: Cirrhotic Cardiomyopathy Predicts

Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease. Article Links: Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. (Journal of the American College of Cardiology) Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. (Journal of the American College of Cardiology) Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. (Journal of the American College of Cardiology) Article 4: Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. (Journal of the American College of Cardiology) Article 5: Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022. (Transplantation) Full episode page: https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/ Featured Articles Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892617 Summary: The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies. Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892613 Summary: N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management. Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892605 Summary: Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease. Article 4: Adiposity-Related Anthropometrics and Clinical Outcome

Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like right heart function and immunoglobulin light chain cardiac amyloidosis. Key takeaway: New Echo Index Guides Amyloidosis Prognosis.. Article Links: Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study. (International journal of cardiology) Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up. (International journal of cardiology) Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation. (International journal of cardiology) Article 4: Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevation myocardial infarction. (International journal of cardiology) Article 5: Usefulness of STREI: A new index of right heart function in patients with immunoglobulin light chain cardiac amyloidosis. (International journal of cardiology) Full episode page: https://podcast.explainheart.com/podcast/new-echo-index-guides-amyloidosis-prognosis-11-17-25/ Featured Articles Article 1: Duration of atrial fibrillation and cardiac biomarkers are associated with cardiovascular outcomes in early permanent atrial fibrillation: Data from the RACE II study. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40716680 Summary: A post-hoc analysis of the RACE two study found that the duration of atrial fibrillation and specific cardiac biomarkers are directly associated with cardiovascular morbidity and mortality in patients with early permanent atrial fibrillation. Data from 543 patients, who had a median atrial fibrillation duration of 18 months, demonstrated these associations. The study identified these parameters as definitive prognostic indicators for adverse cardiovascular outcomes. These findings underscore the clinical importance of assessing atrial fibrillation duration and cardiac biomarker levels for risk stratification in early permanent atrial fibrillation. Article 2: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients are associated with increased rates of all-cause mortality and cardiac death at five years follow-up. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40716679 Summary: This study found that high admission levels of interleukin-1 receptor antagonist are associated with increased rates of both all-cause mortality and cardiac death in patients with acute myocardial infarction. The data demonstrated these elevated levels were linked to adverse outcomes at five years follow-up. This concrete association suggests interleukin-1 receptor antagonist serves as a prognostic biomarker for long-term cardiovascular risk in this patient population. Article 3: Impact of diagnosis-to-ablation time on rhythm outcome after catheter ablation for paroxysmal versus non-paroxysmal atrial fibrillation. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40712675 Summary: This study found that diagnosis-to-ablation time significantly impacts rhythm outcome following catheter ablation for atrial fibrillation. The research differentiated this impact between paroxysmal and non-paroxysmal atrial fibrillation types among 619 enrolled patients. Results indicated that the timing of intervention relative to diagnosis plays a crucial role in the success of initial catheter ablation procedures. This finding provides direct guidance for optimizing treatment strategies based on atrial fibrillation type. Article 4: Global and segmental longitudinal and radial strain in Takotsubo versus ST-elevat

Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like cardiac phenotype and S. L. C. 6 A. 8 variants. Key takeaway: ElectroPulse PFA: First-in-Human Data. Article Links: Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants. (Heart rhythm) Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation. (Heart rhythm) Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis. (Heart rhythm) Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset. (Heart rhythm) Article 5: Added diagnostic value of Electrophysiological study in new-onset Left Bundle Branch Block after transcatheter aortic valve implantation. (The Canadian journal of cardiology) Full episode page: https://podcast.explainheart.com/podcast/electropulse-pfa-first-in-human-data-11-17-25/ Featured Articles Article 1: Prominent U-waves Without QT Prolongation in X-linked Creatine Transporter Deficiency Caused by SLC6A8 Variants. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242588 Summary: T. Prolongation in X-linked Creatine Transporter Deficiency Caused by S. L. C. 6 A. 8 Variants. Complete results detailing the cardiac phenotype of male Creatine Transporter Deficiency patients were not available in the abstract. This study focused on characterizing cardiac manifestations in patients with S. L. C. 6 A. 8 variants. Early clinical reports had raised concerns regarding possible associations with Q. T. c. prolongation and dilated cardiomyopathy in this patient population. Therefore, no definitive outcomes from this study can be reported based on the abstract. Article 2: Update on First-in-Human Experience of High-Energy ElectroPulse Pulsed Field Ablation. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242587 Summary: Complete results, including specific numerical findings for the primary endpoint, were not available in the abstract. This first-in-human study evaluated mid-term outcomes of the ElectroPulse pulsed field ablation system for pulmonary vein and posterior wall isolation. The trial enrolled 60 patients with symptomatic atrial fibrillation, with two cohorts receiving either a standard or a modified ablation protocol. Therefore, no definitive outcomes from this study can be reported based on the abstract. Article 3: Atrioventricular Block After Transcatheter Atrial Septal Defect Closure: Comprehensive Short-term to Long-Term Outcome Analysis. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242586 Summary: Complete results detailing the incidence, risk factors, and outcomes of atrioventricular block following transcatheter atrial septal defect closure were not available in the abstract. The study retrospectively analyzed 1954 patients who underwent transcatheter atrial septal defect closure between 1999 and 2020 at three tertiary centers. This comprehensive analysis uniquely focused on providing detailed short-term to long-term follow-up. Therefore, no definitive outcomes from this study can be reported based on the abstract. Article 4: Device-Based Longitudinal Monitoring of Premature Atrial Contractions Before Atrial Fibrillation Onset. Journal: Heart rhythm PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242585 Summary: Specific numerical findings regarding the temporal frequency pattern of premature atrial contractions before atrial fibrillation onset were not available in the abstract. This retrospective study utilized long-term monitoring data from cardiovascular implantable electronic devices. It included 101 patients from Boston Scientific devices with a mean follow-up of 5.2 years, divided into groups based on whether they developed atrial fibrillation. Therefore, no definitive outcome

Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence. Article Links: Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. (Heart rhythm) Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. (Heart rhythm) Full episode page: https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/ Featured Articles Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242357 Summary: The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract. Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242356 Summary: This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract. Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242355 Summary: This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists

Welcome to Cardiology Today – Recorded November 16, 2025. This episode summarizes 5 key cardiology studies on topics like myocardial performance score and right ventricular failure. Key takeaway: Simplified DCD Heart Tx: 100 percent Graft Function.. Article Links: Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 4: Advanced Hemodynamics for Right Ventricular Failure: Evaluating the use of the Myocardial Performance Score. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 5: Ex-vivo Heart Perfusion Attenuates Early Post-Transplant Risk After Prolonged Agonal Period in DCD Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Full episode page: https://podcast.explainheart.com/podcast/simplified-dcd-heart-tx-100-percent-graft-function-11-16-25/ Featured Articles Article 1: DCD Heart Transplantation Using Simplified Direct Procurement: Expanding Access. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241036 Summary: This study successfully performed five heart transplantations using a simplified direct procurement technique from donation after circulatory death donors. All five recipients demonstrated normal cardiac graft function after the procedure. No evidence of rejection was observed during their short-term follow-up period. The approach, which employed cold blood perfusion and preservation solution, proved to be both feasible and logistically efficient. Article 2: Defining the relationships among four tests for assessing antibody-mediated rejection in heart transplants in a prospective, observational study. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241034 Summary: The Trifecta-Heart study compared four tests used to assess antibody-mediated rejection in heart transplant patients: standard endomyocardial biopsy histology, endomyocardial biopsy molecular analysis using the Molecular Microscope Diagnostic System, donor-derived cell-free D. N. A., and donor-specific antibody measurements. Specific numerical results defining the relationships among these tests were not provided in the abstract. The abstract focused on the comparison of these assessment methods. Article 3: Low Rates of Inotropic Support and Durable Left Ventricular Assist Device Placement among Status 2 Heart Transplant Candidates with Temporary Mechanical Circulatory Support. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41241033 Summary: Following the 2018 heart allocation policy change, status two listings for heart transplant candidates with temporary mechanical circulatory support were observed to increase, while listings for durable left ventricular assist devices decreased. The study identified ad

Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like ventricular systolic function and congenital heart disease. Key takeaway: Albuminuria and Acute Heart Failure Risk. Article Links: Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. (ESC heart failure) Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. (ESC heart failure) Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function. (Cardiology) Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment. (The Canadian journal of cardiology) Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications. (The Canadian journal of cardiology) Full episode page: https://podcast.explainheart.com/podcast/albuminuria-and-acute-heart-failure-risk-11-15-25/ Featured Articles Article 1: Transcriptomic and proteomic profiling shows dysregulated immune and metabolic pathways in arrhythmogenic cardiomyopathy. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41229088 Summary: Complete results were not available in the abstract. This study aimed to characterize the myocardial transcriptome and proteome in patients with arrhythmogenic cardiomyopathy. Specific numerical findings on which immune and metabolic pathways were dysregulated, or the detectability of key molecules in plasma and tissue, were not provided. Article 2: Albuminuria is associated with worse outcomes in non-diabetics hospitalized with acute heart failure. Journal: ESC heart failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224248 Summary: Complete results were not available in the abstract. This study evaluated if albuminuria was associated with adverse outcomes in non-diabetic individuals hospitalized with acute heart failure. Specific numerical findings regarding the association between albuminuria and patient outcomes were not provided. Article 3: Prognostic Determinants in Patients with Secondary Tricuspid Regurgitation Classified by Right Ventricular Systolic Function. Journal: Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41231743 Summary: Complete results were not available in the abstract. This retrospective study aimed to stratify patients with severe secondary tricuspid regurgitation based on right ventricular fractional area change. Specific echocardiographic parameters influencing prognosis or definitive conclusions on patient stratification were not provided. Article 4: Activation of endothelial TRPV4 exacerbates myocardial ischemia-reperfusion injury via vascular integrity impairment. Journal: The Canadian journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41238115 Summary: Complete results were not available in the abstract. This study hypothesized that endothelial transient receptor potential vanilloid 4 contributes to post-ischemic vascular hyperpermeability and myocardial injury. Specific numerical findings demonstrating the exacerbation of ischemia-reperfusion injury or the impairment of vascular integrity were not provided. Article 5: Echocardiographic Indices of Ventricular Systolic Function in Adults with Fontan Palliation: Feasibility, Reproducibility, and Prognostic Implications. Journal: The Canadian journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41238114 Summary: Complete results were not available in the abstract. This retrospective cohort study assessed the feasibility and reproducibility of echocardiogram-derived systolic function indices in adults with Fontan palliation. Specific numerical findings on the relationship between these indices and clinical outcomes were not p

Welcome to Cardiology Today – Recorded November 15, 2025. This episode summarizes 5 key cardiology studies on topics like Transcatheter aortic valve replacement and Heart failure. Key takeaway: PA-Led Heart Transplant Recovery: Safe, Effective. Article Links: Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center. (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons) Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. (Heart (British Cardiac Society)) Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. (Heart (British Cardiac Society)) Article 4: Incidence, predictors and outcomes of tricuspid regurgitation progression after left-sided valvular intervention. (Heart (British Cardiac Society)) Article 5: Determinants of diuresis/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure. (ESC heart failure) Full episode page: https://podcast.explainheart.com/podcast/pa-led-heart-transplant-recovery-safe-effective-11-15-25/ Featured Articles Article 1: Implementation of a Physician Assistant-Led Recovery Model for Heart Transplantation: Clinical Outcomes and Programmatic Benefits at a High-Volume Center. Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41238023 Summary: This observational cohort study assessed the clinical outcomes and programmatic benefits of a physician assistant-led allograft recovery model for adult heart transplantation. Researchers compared 130 transplantations using physician assistant teams with 367 using non-physician assistant teams at a high-volume center between 2020 and 2024. The implementation of this physician assistant-led model for donor organ recovery demonstrated comparable clinical outcomes for heart transplantation recipients. This model offers significant programmatic advantages, potentially enhancing efficiency and resource utilization within heart transplantation programs. Article 2: Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40393691 Summary: This subanalysis of the Low-Dose Colchicine 2 Trial aimed to investigate the effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition. Researchers performed cross-sectional computed tomography angiography studies in 151 participants with chronic coronary disease. The primary objective was to understand the underlying mechanisms by which low-dose colchicine, administered at 0.5 mg once daily, reduces the risk of major cardiovascular events. This study established a methodology to assess how colchicine may exert its beneficial anti-inflammatory actions on coronary arteries. Article 3: Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. Journal: Heart (British Cardiac Society) PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40348411 Summary: This prospective registry study investigated the incidence, predictors, and clinical impact of late upper gastrointestinal bleeding following transcatheter aortic valve replacement. Researchers analyzed 3144 patients, stratifying them based on the occurrence of upper gastrointestinal bleeding within one year of hospital discharge. The study characterized the frequency of this complication in transcatheter aortic valve replacement patients and identi

Welcome to Cardiology Today – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity. Article Links: Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. (The New England journal of medicine) Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. (Circulation) Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. (European heart journal) Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. (European heart journal) Article 5: Exploring postmortem practices for cardiac device interrogation in the UK. (Heart (British Cardiac Society)) Full episode page: https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/ Featured Articles Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159885 Summary: This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study’s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population. Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41230611 Summary: The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment. Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879135 Summary: The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator u

Welcome to Cardiology Today – Recorded November 13, 2025. This episode summarizes 5 key cardiology studies on topics like pediatric cardiology and subclinical atrial fibrillation. Key takeaway: N-Palmitoyl Glutamine: Fitness Mediator. Article Links: Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. (Circulation) Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. (Circulation) Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications. (European heart journal) Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. (Journal of cardiac failure) Article 5: Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. (JAMA cardiology) Full episode page: https://podcast.explainheart.com/podcast/n-palmitoyl-glutamine-fitness-mediator-11-13-25/ Featured Articles Article 1: Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221593 Summary: This study aimed to assess the prognostic relevance of tricuspid regurgitation quantification and its consequences using cardiac magnetic resonance in a large real-world cohort. Researchers collected comprehensive clinical, echocardiographic, and cardiac magnetic resonance data from patients referred between 2019 and 2024 who underwent tricuspid regurgitant fraction quantification. The study established that cardiac magnetic resonance quantification can quantitatively identify high-risk tricuspid regurgitation patients. This provides a crucial tool for improved risk stratification and management strategies for individuals with tricuspid regurgitation. Article 2: N-Palmitoyl Glutamine Is a Candidate Mediator of Cardiorespiratory Fitness. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41221589 Summary: This study investigated the molecular underpinnings of cardiorespiratory fitness, a key predictor of survival and cardiometabolic health. Researchers employed nontargeted liquid chromatography-mass spectrometry-based plasma metabolomics in 654 participants from the HERITAGE Family Study. The study successfully identified N-Palmitoyl Glutamine as a candidate mediator of cardiorespiratory fitness. This discovery provides a novel molecular target for understanding and potentially enhancing cardiorespiratory health and its benefits. Article 3: Cellular and molecular imaging of coronary atherosclerosis: clinical applications. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41222955 Summary: This article reviewed the substantive advances in non-invasive and invasive structural imaging techniques used to delineate atheroma burden and anatomical composition in coronary artery disease. Driven by progress in imaging agent and hardware technology, the review detailed the burgeoning field of cellular and molecular imaging. It comprehensively discussed how these advancements enhance understanding of atherosclerosis pathogenesis and explored their diverse clinical applications. This provides clinicians with critical insights into improved diagnostic capabilities and potential for more targeted therapeutic strategies. Article 4: Contemporary Waitlist and Post-Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis. Journal: Journal of cardiac failure PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224169 Summary: This international multi-institutional study provided contemporary data on waitlist and post-heart transplant outcomes for pediatric patients with Fontan circulation. Researchers conducted a retrospective analysis of children aged 2 to less than 18 years listed for heart transplant in the Pediatric Heart Transplant Society database between 1993 and 2023. The study categorized

Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like monotherapy and exercise hemodynamics. Key takeaway: Angina Endotypes: Precision Treatment Advances. Article Links: Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. (Circulation) Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications. (European heart journal) Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. (European heart journal) Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? (European heart journal) Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: Multicenter Study. (Journal of cardiac failure) Full episode page: https://podcast.explainheart.com/podcast/angina-endotypes-precision-treatment-advances-11-12-25/ Featured Articles Article 1: miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41208706 Summary: This study investigated the mechanisms by which myocardial infarction triggers myelopoiesis and exacerbates disease pathology. Researchers induced myocardial infarction in mice and found that platelet-derived extracellular vesicles containing micro-R. N. A. minus 499 augmented inflammatory cell generation and cardiac remodeling. This discovery indicates that micro-R. N. A. minus 499 from platelet extracellular vesicles plays a critical role in promoting adverse cardiac remodeling and identifies a potential therapeutic target. Article 2: Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217874 Summary: This research explored the role of adaptive immune responses in human atherosclerosis progression. Using R. N. A. sequencing and immunohistochemistry on human atherosclerotic plaques, the study revealed that enhanced antigen presentation by macrophages promotes the disease. This finding highlights the critical involvement of macrophage-driven immune responses in atherosclerosis pathology and suggests novel therapeutic strategies targeting this pathway. Article 3: Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41214896 Summary: This prospective multicenter study aimed to better diagnose and treat angina with non-obstructive coronary arteries, a prevalent myocardial ischemic syndrome. Researchers enrolled consecutive patients undergoing coronary functional testing across nine centers to identify distinct hemodynamic endotypes. The study successfully stratified patients into these endotypes, demonstrating differential responses to specific treatments and thereby establishing a foundation for a precision medicine approach. Article 4: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211721 Summary: While aspirin has been the traditional cornerstone antiplatelet therapy, the review highlights emerging evidence suggesting P2Y12 inhibitors may be more than just an alternative. The findings suggest that P2Y12 inhibitors may be preferred over aspirin as a single antiplatelet agent, offering a significant therapeutic consideration for clinicians. Article 5: Association of Moderate to Severe Tricuspid Regurgitation With Exercise Hemodynamics and Outcomes in Patients With Heart Failure With Preserved E

Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via B2 Cells. Article Links: Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. (Journal of the American College of Cardiology) Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. (Circulation) Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. (Circulation) Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. (Circulation) Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. (Circulation) Full episode page: https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/ Featured Articles Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217319 Summary: The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a). Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40859845 Summary: This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease. Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212997 Summary: This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates. Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212981 Summary: Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in O

Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like congenital heart disease and transmitral mean pressure gradient. Key takeaway: Optimize Mitral Repair: Gradients & Regurgitation. Article Links: Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. (The New England journal of medicine) Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis. (Journal of the American College of Cardiology) Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways. (Journal of the American College of Cardiology) Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair. (Journal of the American College of Cardiology) Article 5: Computed Tomography Angiography or Standard Care After Left Main PCI? (Journal of the American College of Cardiology) Full episode page: https://podcast.explainheart.com/podcast/optimize-mitral-repair-gradients-regurgitation-11-11-25/ Featured Articles Article 1: Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211917 Summary: This multicenter, randomized, open-label, noninferiority trial in South Korea investigated non-vitamin K antagonist oral anticoagulant monotherapy compared to combination therapy. The study enrolled patients with atrial fibrillation who had received a drug-eluting stent at least one year prior. This research aims to provide crucial data to guide antithrombotic management after drug-eluting stent implantation in patients with atrial fibrillation, addressing current limitations in evidence-based guidelines. The primary objective is to determine if non-vitamin K antagonist oral anticoagulant monotherapy is noninferior to combination therapy for these specific patients. Article 2: Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41193094 Summary: This study conducted a secondary analysis to evaluate the effectiveness and safety of risk stratification using high-sensitivity cardiac troponin in the emergency department. While high-sensitivity cardiac troponin pathways are known to reduce length of stay and hospital admissions for myocardial infarction rule-out, this research aimed to confirm these benefits across low and intermediate risk patients. It also sought to ascertain if patients discharged were accurately identified as having a low risk of future cardiovascular events, thereby ensuring patient safety and appropriate resource utilization. Article 3: Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41193091 Summary: This study investigated the impact of placental malperfusion on outcomes in fetuses diagnosed with congenital heart disease. It aimed to determine if congenital heart disease fetuses with placental malperfusion experience adverse outcomes and exhibit genomic variations in shared vascular or placental developmental pathways. This research contributes to understanding the complex interplay between placental health and fetal cardiac development, potentially identifying novel risk factors and mechanisms. This foundational work could lead to improved risk stratification and targeted interventions for congenital heart disease. Article 4: Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After T

Welcome to Cardiology Today – Recorded November 11, 2025. This episode summarizes 5 key cardiology studies on topics like triglycerides and antisense oligonucleotide. Key takeaway: CRISPR-Cas9 Gene Editing for Lipids. Article Links: Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. (The New England journal of medicine) Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. (The New England journal of medicine) Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (The New England journal of medicine) Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (The New England journal of medicine) Article 5: Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. (The New England journal of medicine) Full episode page: https://podcast.explainheart.com/podcast/crispr-cas9-gene-editing-for-lipids-11-11-25/ Featured Articles Article 1: Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211954 Summary: This meta-analysis was conducted at the individual-patient level to clarify the benefit of beta-blockers following myocardial infarction in patients with a preserved left ventricular ejection fraction of at least 50 percent. Using data from five open-label trials, the research established a robust methodology to evaluate clinical outcomes. It specifically aimed to determine the impact of beta-blocker therapy versus no therapy on a primary composite endpoint, addressing a critical area of clinical uncertainty in this patient population. This study helps establish clinical guidance for beta-blocker use after myocardial infarction in patients without significantly reduced ejection fraction. Article 2: Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211945 Summary: This phase 1 ascending-dose trial was conducted to assess the safety and efficacy of CTX310, a lipid-nanoparticle-encapsulated clustered regularly interspaced short palindromic repeats-Cas9 endonuclease targeting ANGPTL3. The rationale for this gene-editing therapy is based on observed ANGPTL3 loss-of-function genetic variants, which are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides, and a reduced lifetime risk of atherosclerotic cardiovascular disease. This study represents an important first step in investigating a novel gene-editing approach to lipid management, potentially offering a transformative therapeutic strategy for cardiovascular disease prevention. The research establishes foundational data for a promising new class of treatments aimed at modifying genetic risk factors. Article 3: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211931 Summary: This international, open-label, randomized trial involving 1284 patients aimed to determine if successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy. Patients had undergone successful ablation at least 1 year earlier and had a C.H.A.2.D.S.2.-V.A.S.c score of 1 or more, or 2 or more for women. The study employed a blinded-outcome-assessment design to rigorously compare antithrombotic strategies. This research is crucial for optimizing post-ablation care and could significantly reduce treatment burden for patients with atrial fibrillation. Article 4: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41211925 Summary: This international, double-blind, randomized, placebo-controlled trial investigated the effect of the proprotein convertase

Welcome to Cardiology Today – Recorded November 10, 2025. This episode summarizes 5 key cardiology studies on topics like Coronary function testing and sodium-glucose cotransporter two inhibitors. Key takeaway: Aspirin Withdrawal Lowers LVAD Bleeding. Article Links: Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. (Circulation) Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (European heart journal) Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. (European heart journal) Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. (European heart journal) Article 5: Clonal Hematopoiesis and Incident Heart Failure. (JAMA cardiology) Full episode page: https://podcast.explainheart.com/podcast/aspirin-withdrawal-lowers-lvad-bleeding-11-10-25/ Featured Articles Article 1: Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206792 Summary: The DARE-AF Randomized Clinical Trial investigated the effect of dapagliflozin on preventing early atrial fibrillation recurrence following catheter ablation. This randomized study focused on patients without established indications for sodium-glucose cotransporter two inhibitors like diabetes, heart failure, or chronic kidney disease. The trial aimed to determine if dapagliflozin could reduce recurrence in this broader population, building on observational data suggesting such benefits in other patient groups. The research specifically explored a potential new therapeutic application for dapagliflozin in post-ablation atrial fibrillation management. Article 2: Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41206679 Summary: The ARIES-HM3 trial demonstrated that aspirin can be safely omitted from the antithrombotic regimen for patients with a HeartMate three left ventricular assist device who are also receiving vitamin K antagonists. This randomized study found that withdrawing aspirin significantly reduced bleeding events without increasing thrombotic risks. The research also highlighted that high quality vitamin K antagonist management, assessed by Time in Therapeutic Range, is crucial for optimal outcomes. This advancement provides a simplified and safer antithrombotic strategy for advanced heart failure patients with left ventricular assist devices. Article 3: Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40796244 Summary: The A.S.P.R.E.E. trial conducted an extended follow-up to assess the long-term effects of low-dose aspirin on major adverse cardiovascular events and major hemorrhage in older adults. This research analyzed both in-trial data from 2010 to 2017 and post-trial data from 2017 to 2022. The study cohort included participants aged 70 years or older, or 65 years and older for U.S. minorities, focusing on primary prevention of atherosclerotic cardiovascular disease events. The extended follow-up aimed to provide crucial long-term evidence to inform clinical guidelines on aspirin use in this vulnerable population. Article 4: Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial. Journal: European heart journal PubMed Link: https://pubmed